Valeant Pharmaceuticals International, Inc. (VRX) Tops Q4 EPS by 10c
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) reported Q4 EPS of $0.94, $0.10 better than the analyst estimate of $0.84. Revenue for the quarter came in at $688.4 million, versus $514.56 million reported last year.
For earnings history and earnings-related data on Valeant Pharmaceuticals International, Inc. (VRX) click here.
For earnings history and earnings-related data on Valeant Pharmaceuticals International, Inc. (VRX) click here.